Health Tech Earnings: AI Integration and Orphan Drugs Drive Q4 Sector Growth

The fourth-quarter 2025 earnings season has highlighted a significant divergence within the healthcare and health IT sectors, defined by the rapid scaling of specialized therapeutics and the deepening integration of artificial intelligence in diagnostics. As legacy medical device manufacturers navigate fluctuating capital equipment cycles, the market is increasingly rewarding companies that possess high-margin, recurring revenue streams and proprietary technology platforms. This shift is most evident in the performance of diagnostic leaders and orphan drug specialists who have successfully transitioned from clinical development to robust commercial execution.

Veracyte (VCYT) emerged as a standout in the diagnostic space, reporting a 19% year-over-year revenue increase to $140.6 million. The company’s success is anchored by its Decipher and Afirma tests, which saw 27% and 16% revenue growth, respectively. Crucially, Veracyte’s transition to its v2 transcriptome platform has not only lowered costs but also improved diagnostic accuracy, allowing the company to exceed its 25% adjusted EBITDA margin target a full year ahead of schedule. This move exemplifies a broader trend where health IT and diagnostic firms are leveraging advanced genomic data and automated platforms to drive operational leverage and clinical utility simultaneously.

“

Veracyte (VCYT) emerged as a standout in the diagnostic space, reporting a 19% year-over-year revenue increase to $140.6 million.

In the therapeutics and orphan drug segment, Soleno Therapeutics (SLNO) and Mirum Pharmaceuticals (MIRM) demonstrated the immense financial potential of addressing unmet needs in rare diseases. Soleno achieved a historic pivot to profitability, reporting $20.9 million in net income for the fiscal year—a staggering recovery from a $175.9 million loss in the prior year. The launch of VICAT XR for Prader-Willi syndrome has seen rapid uptake, with 1,250 patient start forms representing 12.5% of the addressable U.S. market. Similarly, Mirum reported a 55% surge in annual revenue to $521 million, driven by the strong performance of Livmarli. These results suggest that the 'orphan drug model' remains highly resilient, as specialized patient populations provide a protected market with significant pricing power and lower sensitivity to broader economic volatility.

The medical device and surgical sectors presented a more nuanced picture. MiMedx (MDXG) reported robust 27% growth in net sales, reaching $118 million, despite facing new Medicare reimbursement caps for skin substitutes. By maintaining an 86% adjusted gross margin through a favorable product mix, MiMedx demonstrated that innovation in wound care and surgical biologics can offset regulatory headwinds. Conversely, RxSight (RXST) experienced a 19% decline in total sales, primarily due to a sharp drop in Light Delivery Device (LDD) placements. However, RxSight’s record-high 77.5% gross margin—driven by its recurring Light Adjustable Lens (LAL) sales—highlights a successful 'razor-and-blade' strategy that prioritizes high-margin consumables over one-time hardware sales.